Search

Your search keyword '"Wanner, C."' showing total 1,830 results

Search Constraints

Start Over You searched for: Author "Wanner, C." Remove constraint Author: "Wanner, C."
1,830 results on '"Wanner, C."'

Search Results

1. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

2. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

4. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

7. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension

10. Numerical modeling of cold magmatic CO2 flux measurements for the exploration of hidden geothermal systems

11. Processes controlling δ7Li in rivers illuminated by study of streams and groundwaters draining basalts

13. Pulse pressure and mortality in the 4D study

14. The relationship between uremic toxins and symptoms in older men and women with advanced chronic kidney disease

15. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease.

17. Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study

18. Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes

19. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.

20. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)

21. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)

22. Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)

23. Fabry-Krankheit

24. From WEDA to EDTA to ERA: 60 years of supporting European nephrology and counting

27. The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study

28. Renal function decline in older men and women with advanced chronic kidney disease-results from the EQUAL study

29. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease

30. In patients with type 2 diabetes chronic kidney disease is a modifiable cardiovascular risk factor

31. Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials

32. Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction – EMPEROR-Preserved trial

36. Sodium-Glucose co-Transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: A new era has already begun

37. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

39. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME

40. Cardiovascular and renal outcomes with empagliflozin in heart failure

43. Reply to 'Depression and clinical outcomes in CKD: do anti-depressants play a role? (EQUAL Study)'

44. Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression

47. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

50. Proteinurie

Catalog

Books, media, physical & digital resources